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Objectives: Because the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of colistin against
Enterobacteriaceae are not well explored, we studied the activity of colistin against K. pneumoniae in an in vitro
PK/PD model simulating different dosing regimens.
Methods: Three clinical isolates of K. pneumoniae with MICs of 0.5, 1 and 4 mg/L were tested in an in vitro PK/PD
model following a dose-fractionation design over a period of 24 h. A high and low inoculum of 107 and 104 cfu/mL
with and without a heteroresistant subpopulation, respectively, were used. PK/PD indices associated with colistin
activity were explored and Monte Carlo analysis was performed in order to determine the PTA for achieving a
bactericidal effect (2 log kill).
Results: The fAUC/MIC (R2"0.64–0.68) followed by fCmax/MIC (R
2"0.55–0.63) best described colistin’s 24 h
log10 cfu/mL reduction for both low and high inocula. Dosing regimens with fCmax/MIC 6 were always associ-
ated with a bactericidal effect (P"0.0025). However, at clinically achievable concentrations, usually below
fCmax/MIC"6, an fAUC/MIC 25 was more predictive of a bactericidal effect. Using a dosing regimen of 9 MU/
day, the PTA for this pharmacodynamic target was 100%, 5%–70% and 0%, for isolates with MICs of0.5, 1 and
2 mg/L, respectively. Dosing regimens that aim for a trough level of 1 mg/L achieve coverage of strains up to
0.5 mg/L (target trough/MIC"2 mg/L).
Conclusions: Characterization of the pharmacodynamics of colistin against Enterobacteriaceae in an in vitro
model of infection indicates that a revision of current susceptibility breakpoints is needed. Therapeutic drug mon-
itoring of colistin to achieve pharmacodynamic targets in individual patients is highly recommended.
Introduction
The emergence of MDR Gram-negative bacteria, including
carbapenemase-producing Klebsiella pneumoniae (CP-Kp), isolates
has led to the revival of the use of old antibiotics such as colistin.1,2
Understanding the pharmacodynamics of colistin against CP-Kp is
important in order to optimize antimicrobial therapy against these
infections. Although there are several preclinical pharmacokinetic/
pharmacodynamic (PK/PD) studies of Pseudomonas aeruginosa
and Acinetobacter baumannii in in vitro pharmacokinetic and
animal models,3 the PK/PD characteristics of colistin against
Enterobacteriaceae have not been extensively explored. Here
we focused on the pharmacodynamics of colistin against
K. pneumoniae, and used an in vitro PK/PD model to simulate
different colistin exposures against low and high inocula. We sub-
sequently calculated the PTA for isolates with different MICs to
evaluate the susceptibility breakpoint of colistin.
Materials and methods
Isolates, drug and medium
Three clinical isolates of K. pneumoniae with colistin CLSI MICs of 0.5 mg/L
(WT TZAN59), 1 mg/L (carbapenemase-producing KPC1433) and 4 mg/L
(verified in quadruplicate experiments) were used. The isolates were
stored at#70C and revived after subculturing on MacConkey agar plates
at 37C for 18–24 h, and final concentrations of 107 and 104 cfu/mL, veri-
fied by quantitative cultures, were used as starting inocula. Colistin sulfate
(Sigma Aldrich, Athens, Greece) and cation-adjusted Mueller–Hinton broth
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
For Permissions, please email: journals.permissions@oup.com.
953
J Antimicrob Chemother 2018; 73: 953–961
doi:10.1093/jac/dkx522 Advance Access publication 25 January 2018
Downloaded from https://academic.oup.com/jac/article-abstract/73/4/953/4825047
by Erasmus Universiteit Rotterdam user
on 16 April 2018
were used according to CLSI instructions.4 The two inocula were chosen
based on preliminary experiments to assess the presence of heteroresist-
ant subpopulations. Briefly, 100lL of 10-fold increasing inocula
(103–107 cfu/mL) of TZAN59 and KPC1433 isolates were cultured on
Mueller–Hinton agar containing 2-fold concentrations of colistin ranging
from 2 to 64 mg/L and the number of colonies grown after 24 h were
counted and MICs determined. No resistant subpopulations were found at
inocula up to 104 cfu/mL whereas 1–13 cfu were grown on Mueller–Hinton
agar containing 8–32 mg/L with the 107 cfu/mL inoculum.
In vitro PK/PD model
A previously developed closed diffusion/dialysis in vitro pharmacokinetic
model was used in the present study in order to simulate the pharmacoki-
netics of colistin in humans and to study its antibacterial effect.5,6 A dose-
fractionation design was followed with nine dosing regimens of colistin tar-
geting fCmax 9, 3 and 1.5 mg/L administered every 8, 12 and 24 h for 24 h.
High drug exposures were included in order to better describe the
exposure–effect relationships with effects ranging from low to high. Colistin
was added to both compartments of the in vitro model in order to reach a
peak concentration within 1.5 h, simulating exposures achieved with a load-
ing dose followed by maintenance doses. The activity of additional dosing
regimens with increasing fCmax and longer half-lives was also assessed.
Drug concentrations in the internal compartment were determined with a
microbiological diffusion assay using 106 cfu/mL Escherichia coli ATCC
25922 impregnated in antibiotic medium 10 agar in Mueller–Hinton broth
(Difco, Athens, Greece) (concentration range 0.25–16 mg/L with r2"0.98
and inter-day variation,7%).7
PK/PD analysis
The PK/PD relationships were analysed by non-linear regression using the
Emax model described by the equation E" Emax% (EI/EI50)
m/[1! (EI/
EI50)
m], where E is the bacterial load at the end of experiment (dependent
variable) in log10 cfu/mL, EI is the PK/PD index fCmax/MIC, fAUC/MIC or
%fT.MIC (independent variable), Emax is the maximum bacterial load in
log10 cfu/mL observed in the drug-free control group, EI50 is the EI corre-
sponding to 50% of Emax and m is the slope of the concentration–effect
curves (Hill coefficient) (GraphPad Prism 4.03, San Diego, CA). Colistin expo-
sures associated with a bacteriostatic effect (i.e. no change compared with
the initial inoculum after 24 h) and a 2 log kill effect (i.e. 2 log10 cfu/mL
reduction from initial inoculum) were calculated. The 2 log kill effect in the
present model was previously found to be associated with 1 log kill in a
thigh infection murine model.8 In order to capture pharmacodynamic
effects for the entire 24 h period, a similar analysis was performed using the
area under the 24 h time–kill curve (AUTKC) normalized to span from 100%
(drug-free control) to 0% (log10 LOD%24). Bactericidal effects were ana-
lysed with classification and regression tree (CART) analysis, using as a
response the presence of bactericidal activity as the nominal value and all
three PK/PD indices as continuous variables. The results of the CART analysis
were assessed statistically with Fisher’s exact test.
Monte Carlo simulations and analysis
The probability of attaining a 2 log kill effect against K. pneumoniae isolates
was calculated by applying Monte Carlo simulations of 5000 patients with
normal renal function (mean CLCR 85–105) treated with either 9 MU q24h,
4.5 MU q12h or 3 MU q8h. These dosing regimens were previously found
to result in tCmax+ SD 5.83+0.87, 2.98+0.27 and 3.34+0.35 mg/L; total
tCmin+ SD 2.60+1.12, 2.01+0.47 and 1.63+0.23 mg/L; and tAUC0–24+ SD
72.93+38.57, 60.71+12.0 and 50.18+10.74 mgh/L, respectively.9 The
Monte Carlo simulation was performed using the normal random number
generator function of Excel (MS Office 2007) and the corresponding fCmax
and fAUC were calculated based on the 40% of unbound fraction of colistin
in human serum.8 The PK/PD PTA associated with a 2 log kill effect was
calculated for each MIC and dosing regimen. The PTA at the epidemiologi-
cal cut-off (ECOFF) of colistin for K. pneumoniae (2 mg/L) was also
estimated.
The cumulative fraction of response (CFR)10 was calculated for
K. pneumoniae with the WT MIC distribution as presented on the EUCAST
web site with the following frequencies: 1%, 20%, 55%, 18% and 2%
for MICs 0.125, 0.25, 0.5, 1 and 2 mg/L, respectively. In addition, the
CFR was also calculated for a hypothetical collection of isolates with MICs
shifted by one, two and three 2-fold dilutions higher than the EUCAST MIC
distribution described above, resulting in three MIC distributions with
modal MICs of 1, 2 and 4 mg/L and resistance rates (isolates with MIC
.2 mg/L) of 3%, 20% and 73%, respectively. Finally, the trough levels
required with each dosing regimen in order to achieve a bactericidal effect
for isolates with increasing MICs were calculated taking into account the
40% unbound fraction,8 a 1/30 AUC/Cmin ratio
9 and a t1=2 of 12 h.
9,11
Results
In vitro pharmacodynamics
For the higher inoculum, after a concentration-dependent
decrease in log10 cfu/mL within the first 2 h, regrowth was
observed for some dosing regimens, in particular for the strain
KPC1433 (Figure 1). A 2 log kill effect was observed for the q8h dos-
ing regimen with fCmax 1 mg/L. For regimens with longer dosing
intervals, a bactericidal effect was observed for the q12h dosing
regimens with fCmax 4.5 for KPC1433, and fCmax 0.75 mg/L for
TZAN59 and for the q24h dosing regimens with fCmax 6 mg/L for
KPC1433 and fCmax 3 mg/L for TZAN59. Resistant subpopulations
were found at both t"0 h and t"24 h. The MICs of these popula-
tions were higher (32 mg/L) than the MICs of the initial isolates.
For the lower inoculum, a decrease in log10 cfu/mL was also
observed within 2 h. However, this was not concentration depend-
ent since all dosing regimens reduced bacterial load to below the
LOD (data not shown). No resistant subpopulations were found at
t"0 h and t"24 h. The MICs of colonies grown on drug-free
media at 24 h were similar to the MICs of initial isolates, whereas
the MICs of colonies grown on colistin-containing media were
higher.
In vitro PK/PD relationships
The PK/PD relationships for the 24 h log10 cfu/mL and the
24 h AUTKC are shown in Figure 2. For the highest inoculum of
107 cfu/mL and the 24 h log10 cfu/mL change, the R
2 for all three
PK/PD indices were in the range 0.55–0.68, with the fAUC/MIC
showing the highest R2. Large variability between the two strains
was observed for intermediate exposures (fAUC/MIC 10–30 and
fCmax/MIC 1–4) with 24 h log10 cfu/mL change varying from 2 log10
growth to 6 log10 kill. This variability was minimized when the 24 h
AUTKC was used to express outcome as a function of fAUC/MIC,
giving a slightly higher R2 (0.90) compared with fCmax/MIC
(R2"0.83) and %fT.MIC (R
2"0.79). The largest variability was
again observed at intermediate drug exposures with effects vary-
ing from 20% to 80% of Emax.
Similar results were found with the lower inoculum with both
fAUC/MIC (R2" 0.64 for 24 h log10 cfu/mL change and R
2"0.76 for
24 h AUTKC) and fCmax/MIC (R
2"0.63 for 24 h log10 cfu/mL change
and R2"0.62 for 24 h AUTKC), which clearly offer a better descrip-
tion than than %fT.MIC (R
2"0.51 for 24 h log10 cfu/mL change
and R2"0.44 for 24 h AUTKC) (data not shown).
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Given the relatively small R2 of exposure–effect relationships,
CART analysis was performed in order to determine an EI strongly
associated with a 2 log kill effect. CART analysis showed that both
fCmax/MIC and fAUC/MIC were associated with 2 log kill for the high
inoculum. Dosing regimens with an fCmax/MIC ratio of 6 and an
fAUC/MIC ratio of 30 resulted in 100% (10/10) 2 log kill, whereas
this was only 38% (6/16) with lower fCmax/MIC and fAUC/MIC ratios
(P"0.0014). Likewise, for the low inoculum, an fCmax/MIC 6
(P"0.0025) and an fAUC/MIC ratio of 25 (P"0.013) was associ-
ated with 2 log kill.
In order to elucidate the impact of fCmax and fAUC on colistin
pharmacodynamics separately, dosing regimens with different
fCmax and fAUCs were simulated in additional experiments in the in
vitro model targeting increasing PK/PD index values. A 1 h infusion
and a 10 h infusion were applied to achieve fCmax 1–6 mg/L and
fAUCs varying from 7.5 to 32 mgh/L against TZAN59 and
KPC1433. Confirming the results in the initial experiments, a high
fCmax/MIC ratio appeared to have a beneficial effect. A bactericidal
effect was found for dosing regimens with fCmax/MIC 6 against
TZAN59 even with an fAUC/MIC as low as 15 (Figure 3). By contrast,
for dosing regimens with low fCmax/MIC ratios between 1 and 6,
bactericidal effects were less apparent and observed only at high
fAUC/MIC ratios between 30.6 and 61 (Figure 4a and b). In another
set of experiments simulating dosing regimens targeting
fCmax/MIC (fAUC/MIC) ratios of 3 (32), 6 (21), 6 (62) and 12 (42),
complete kill was found for all dosing regimens with either
fCmax/MIC 6 or fAUC/MIC 32 (Figure 4c and d). The simulated
dosing regimens with fCmax 32 mg/L q24h and t1=2"2 h (obtained
fCmax/MIC 6.1 and fAUC/MIC 23.5) and fCmax 16 mg/L q12h and
t1=2"12 h (obtained fCmax/MIC 3.8 and fAUC/MIC 40.6) were
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Figure 1. Time–kill curves of initial dose-fractionation studies in the in vitro model for the K. pneumoniae TZAN59 (left) and KPC1433 (right) isolates
using an initial inoculum of 107 cfu/mL. The horizontal dotted line represents the lower limit of detection (1.7 log10 cfu/mL). The mean+ SD difference
between measured and target peak concentrations was 13+5%.
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effective in achieving a 2 log kill effect of the low-level resistant
K. pneumoniae isolate. Thus, all experiments indicate that both
fCmax/MIC and fAUC/MIC ratios are important targets for efficacy.
Target attainment
Using the results above, the pharmacodynamic targets
fCmax/MIC"6 and fAUC/MIC"25 were chosen in order to esti-
mate the PTA since both targets were associated with 2 log kill
activity against K. pneumoniae. The PTAs are shown in Figure 5 for
the three most often used clinical dosing regimens of 9 MU q24h,
4.5 MU q12h and 3 MU q8h. An fCmax/MIC .6 was attained for
isolates with MIC 0.25 mg/L for most (.90%) patients treated
with 9 MU q24h and for isolates with an MIC0.125 mg/L for most
patients treated with 4.5 MU q12h and 3 MU q8h (similar results
were found with the 3 log kill). However, fAUC/MIC .25 was
attained in 100%, 5%–70% and 0% for isolates with MICs of 0.5,
1 and 2 mg/L, respectively, with all three dosing regimens
(Figure 5). Thus, the PTA was 0 for the current breakpoint of 2 mg/L.
The CFRs for K. pneumoniae isolates following the EUCAST MIC
distribution with a modal MIC of 0.5 mg/L and a resistance rate
(isolates with MIC .2 mg/L) of 2% were comparable for the three
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Figure 2. The in vitro PK/PD relationships fAUC/MIC (top), fCmax/MIC (middle) and %fT.MIC (bottom) of colistin using the 24 h log10 cfu/mL change
compared with the initial inoculum (left graphs) and the normalized percentage area under the 24 h time–kill curve (AUTKC) compared with the
AUTKC of drug-free controls (right graphs) using an initial inoculum of 107 cfu/mL.
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dosing regimens (76%–83%) with the highest CFR found for the
3 MU q8h (Figure 6a). For MIC distributions with higher modal MICs
and resistance rates of 1 mg/L and 3% (Figure 6b), 2 mg/L and
20% (Figure 6c), and 4 mg/L and 73% (Figure 6d), the CFR was
82%, 39%, 8% and 0% for 3 MU q8h, respectively.
The trough levels required to attain a 2 log kill effect for iso-
lates with increasing MICs are shown in Figure 7. In order to attain
the PK/PD target fAUC/MIC.25, the estimated target trough/MIC
ratio was 2, indicating that isolates with an MIC up to 1 mg/L
could be covered with a non-toxic dosing regimen (trough levels
,3.33 mg/L).12 This could just be achieved with 3 MU q8h and
4.5 MU q24h. However, 1 mg/L is below the breakpoint of 2 mg/L
and colistin therapy is therefore marginal at best. Most patients
treated with 9 MU q24h could achieve those levels but the large
interindividual variation and the fact that one-quarter of the
patients would have toxic trough levels indicates the necessity for
therapeutic drug monitoring (TDM).
Discussion
In vitro PK/PD modelling of colistin showed that both fCmax/MIC
and fAUC/MIC described colistin’s activity against low and high
inocula of K. pneumoniae. At low inoculum, regrowth was associ-
ated with adaptive resistance since recovered isolates grown in
drug-free media had low MICs. In contrast, for the high inoculum,
regrowth was associated with heteroresistance since recovered
subpopulations of isolates had high MICs. Dosing regimens with
fCmax/MIC .6 were associated with a .2 log kill effect independ-
ently of fAUC. However, for dosing regimens with lower fCmax/MIC
ratios, an fAUC/MIC.25 appeared to be more predictive of .2 log
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Figure 3. In vitro pharmacodynamics of different dosing regimens with increasing fCmax against the WT (TZAN59) K. pneumoniae isolate. Left graph:
concentration–time profiles of dosing regimens used. Right graph: killing curves of four dosing regimens.
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Figure 4. In vitro pharmacodynamics of different dosing regimens with 1.5 and 10 h infusion and increasing fCmax against (a, c) the carbapenemase-
producing KPC1433 K. pneumoniae isolate, and (b, d) a WT (TZAN59) K. pneumoniae isolate.
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kill activity. Because conventional clinical dosing regimens usually
result in low serum fCmax/MIC ratios, the apparently determining
PK/PD index in patients is the fAUC/MIC. Although the PTA for an
fAUC/MIC .25 was 100% for isolates with an MIC 0.5 mg/L,
it decreased to 0% at 2 mg/L. The latter is the ECOFF for
K. pneumoniae, indicating that colistin is likely not optimally effec-
tive as monotherapy. The clinical breakpoint at present, however,
is 2 mg/L.13 The CFR for WT isolates was 82%, and dropped signifi-
cantly when shifts in distributions were simulated.
The PK/PD properties of colistin against Enterobacteriaceae
have not been previously explored in detail. Preclinical studies on
using colistin in animals against P. aeruginosa and A. baumannii
showed that fAUC/MIC best correlated with bacterial killing.
The fAUC/MIC required for a 1 log10 kill in animal thigh and lung
infections models was 12.2–22.8 for P. aeruginosa and 7–42 for
A. baumannii.3 This is in agreement with the fAUC/MIC found in the
present study against K. pneumoniae. In a previous animal pneu-
monia model using K. pneumoniae, a colistin AUC/MIC of 158.5
was associated with 68% mortality.14 Since colistin protein binding
in mouse serum is 90%–92%,15 the fAUC/MIC should be 12–16,
which is within the fAUC/MIC range found in the present study.
Although fAUC/MIC accurately describes colistin activity,
fCmax/MIC was also closely correlated with colistin activity,
particularly for the low inoculum, in which no heteroresistant sub-
populations were found. For the higher inoculum, including hetero-
resistant subpopulations, the fAUC/MIC was strongly correlated
with colistin activity. However, a concentration-dependent killing
was observed within 2 h with an fCmax/MIC.6 possibly required to
kill the more susceptible subpopulation without affecting the less
susceptible subpopulation for which a high fAUC/MIC .25 was
required in order to prevent regrowth. This may explain why CART
analysis indicated both fCmax/MIC and fAUC/MIC as equally signifi-
cant predictive PK/PD indices for killing the high inoculum. Colistin’s
concentration-dependent killing was previously described against
P. aeruginosa and A. baumannii16,17 and an fCmax/MIC .8–10 was
suggested for other concentration-dependent bactericidal
drugs,18 although fAUC/MIC appears to be the pharmacodynamic
driver.15,19 Similarly, single high doses of azithromycin, an fAUC/
MIC-dependent drug, were more efficacious than multidose regi-
mens in preclinical infection models.20 In contrast to other
concentration-dependent drugs, colistin exerts a strong initial
concentration-dependent killing but no significant post-antibiotic
effect at low, clinically relevant concentrations (1 h at the MIC and
2–3 h at .16%MIC).16,21 In addition, colistin has a relatively long
half-life. However, given that a high fCmax/MIC cannot be obtained
in patients’ serum for isolates with an MIC .0.25 mg/L, the fAUC/
MIC may be the determining PK/PD index in patients.
Based on a PK/PD target of 25 for the fAUC/MIC, Monte Carlo
simulations showed a cumulative fraction of response for the WT
distribution of 77%–83% for all three clinical dosing regimens.
These rates are similar to the clinical cure rate of 82.1% found in
patients with sepsis due to Gram-negative bacteria susceptible
only to colistin and treated with 4.5 MU q12h.22 A similar cure rate
of 83.3% was reported in another retrospective cohort study.23
However, lower clinical cure rates (57%–73%) have been
reported in several retrospective studies in which lower colistin
CMS 9 MU q24h for K. pneumoniae
0.03 0.06 0.125 0.25 0.5 1 2 4 8
0
20
40
60
80
100
CFR=81%
Colistin MIC (mg/L)
PT
A
 (%
)
CMS 4.5 MU q12h for K. pneumoniae
0.03 0.06 0.125 0.25 0.5 1 2 4 8
0
20
40
60
80
100
CFR=77%
Colistin MIC (mg/L)
PT
A
 (%
)
CMS 3 MU q8h for K. pneumoniae
0.03 0.06 0.125 0.25 0.5 1 2 4 8
0
20
40
60
80
100
fAUC/MIC=25
fCmax/MIC=6
EUCAST MIC
CFR=83%
Colistin MIC (mg/L)
PT
A
 (%
)
Figure 5. Probability of target attainment for K. pneumoniae isolates with increasing MICs and three clinical dosing regimens of colistin administered
in ICU patients with normal renal function11 for two PD targets: fAUC/MIC"25 (black line) and fCmax/MIC"6 (grey line). The cumulative fraction of
response (CFR) is shown for a collection of isolates with the EUCAST MIC distribution with a modal MIC of 0.5 mg/L (broken line).
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methanesulphonate (CMS) doses (1–3 MU) were given to patients
with ventilator-associated pneumonia.1 Such low daily doses
would not produce drug exposures sufficient to attain the PK/PD
target for isolates with an MIC of 0.5–1 mg/L.
The lower success rates reported with colistin may be explained
by inefficient drug exposure or infections by less susceptible iso-
lates shifting out of the WT distribution. A recent surveillance
multicentre study recording resistance rates for colistin of
K. pneumoniae, E. coli, P. aeruginosa and A. baumanii isolates from
ICU patients showed that although the resistance rate is low
(,10%), the median MIC is 1 mg/L,24,25 one 2-fold dilution higher
than the median MIC of the WT EUCAST distribution. As shown in
the present study, this increase reduced the PTA rates significantly.
In centres with such a shift in MICs or with higher resistance
rates,26 clinical cure by colistin monotherapy is low and therefore
alternative chemotherapeutic approaches are followed, e.g. com-
bination therapy.27 Comparable high clinical cure rates were found
for colistin monotherapy and combination therapy for isolates
with an MIC of0.5 mg/L.28 Significantly, this MIC was found in the
present study to be the highest MIC offering a reasonable PTA.
The optimal dose should be sufficient to result in a tCmax 7.5 mg/L
(fCmax"3 mg/L) or tAUC of 31.25 mgh/L (fAUC"12.5 mgh/L) for
an isolate with an MIC of 0.5 mg/L (target fCmax/MIC"6 and fAUC/
MIC"25). Although high tCmaxs up to 23 mg/L have been
reported,29 few patients could attain such a high tCmax of 7.5 mg/L
even with the highest dose of 9 MU.9 Thus, the tAUC of 31.25 mgh/L
is a more clinically feasible target for isolates with an MIC of up to
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Figure 6. The cumulative fraction of response (CFR) defined as the population PTA for the 3 MU q8h CMS dose (similar exposures were found for
4.5 MU q12h and 9 MU q24h) in ICU patients with normal renal function11 and a collection of isolates with modal MICs of 0.5 (EUCAST MIC distribu-
tion), 1, 2 and 4 mg/L, with proportions of resistant isolates (MIC .2 mg/L, horizontal dotted line) of 2%, 3%, 20% and 73%, respectively.
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Figure 7. Target drug exposure (total trough levels on the left axis and
total AUC0–24 on the right axis) required to attain the mean (95% CI) PK/PD
target fAUC/MIC of 25 (17–36) and the target tAUC of 62.5 (42.5–90)
against K. pneumoniae isolates with different MICs. The shaded area
indicates increased risk for nephrotoxicity, which is usually associated
with trough levels .3.33 mg/L. The dotted lines represent the 95% CI of
the PK/PD target calculated from the in vitro model. Trough levels of
the three clinical dosing regimens 9 MU q24h, 4.5 MU q12h and 3 MU
q8h in ICU patients with normal renal function9 are shown next to the
left-hand axis.
In vitro pharmacodynamics of colistin JAC
959
Downloaded from https://academic.oup.com/jac/article-abstract/73/4/953/4825047
by Erasmus Universiteit Rotterdam user
on 16 April 2018
0.5 mg/L. Assuming a half-life of 12 h, a trough/MIC ratio of 2 should
be targeted in order to obtain a tAUC of 31.25 mgh/L. Isolates with
an MIC of up to 1 mg/L, which represent 94% of the WT distribution,
could be treated with a dosing regimen that produces a trough level
of 2 mg/L. Isolates with higher MICs would require higher trough lev-
els (.3.33 mg/L), which are associated with an increased risk of
nephrotoxicity.12 An average steady-state trough level of .2 mg/L
has been previously suggested as adequate for treatment of these
infections.30 However, the large interindividual variability in Css,avg
(median 2.35, range 0.24–9.92 mg/L) and in protein binding
(mean+ SD unbound fraction 0.49+0.11 in critically ill patients)31
indicates that most patients would attain the PK/PD target for
isolates with an MIC of up to 0.5 mg/L, whereas for isolates with
an MIC of 1 mg/L, TDM can optimize drug exposure by increasing
efficacy and reducing toxicity. Alternatively, high infrequent
doses (e.g. 12–18 MU q48h or q72h) may optimize both Cmax/MIC
and AUC/MIC indices and reduce trough levels associated with neph-
rotoxicity, although toxicity studies are required to prove the safety
of those dosing regimens.
Based on the PK/PD target of fAUC/MIC .25, a susceptibility
PK/PD breakpoint of 0.5 mg/L was determined in the present
study. This breakpoint is lower than the EUCAST clinical break-
point and ECOFF value of2 mg/L. However, using the latter end-
point, .98% of isolates would be deemed susceptible, whereas
the success rate of colistin monotherapy hardly reaches 80%
against colistin-susceptible isolates based on previous clinical
studies.22 Of note, using the 0.5 mg/L susceptibility breakpoint,
78% would be susceptible. Furthermore, using the 2 mg/L
breakpoint, no difference was found in mortality between
carbapenem-resistant Enterobacteriaceae infections by colistin-
susceptible and colistin-resistant isolates.32 More important is the
finding that the clinical outcomes of colistin therapy in patients
infected with susceptible (MIC2 mg/L) A. baumannii isolates but
high colistin MICs (1–2 mg/L) were poorer than in patients
infected with isolates with lower (,1 mg/L) MICs (7 day outcome
38% versus 20.2%, P"0.025).33 Finally, it was suggested that
current maintenance doses may not be effective against isolates
with an MIC .0.5 mg/l.34 Thus, a revision of the current suscepti-
bility breakpoint for colistin may be needed.
For isolates with an MIC 0.5 mg/L (,50% of the clinical iso-
lates) monotherapy can attain the pharmacodynamic target,
whereas for isolates with an MIC of 1 mg/L, TDM can optimize drug
exposure in order to attain the pharmacodynamic target. Target
attainment rates may be higher for patients with reduced renal
clearance though with increased risk for toxicity. For those
patients, dose adjustments have been recommended based on
creatinine clearance.33 Monotherapy will not be sufficient for iso-
lates with higher MICs and combination therapy should be consid-
ered in order to decrease the pharmacodynamic target by
synergistic interactions. For patients with augmented renal func-
tion, higher CMS doses (12–18 MU) may be used in order to achieve
adequate levels of colistin. Those dose recommendations together
with the nomogram of Figure 7 can be used in order to optimize
CMS dosing regimens for patients with altered renal clearance.
However, dose adjustments based on MICs require reliable and
reproducible MIC testing assays and the in vitro PD target deter-
mined here needs to be comparable with the clinical PD target.
In conclusion, in vitro PK/PD modelling of colistin activity against
K. pneumoniae showed that fAUC/MIC is the best predictor of
colistin activity for clinically achievable concentrations, and fCmax/
MIC the best determinant of colistin bactericidal activity. Colistin
rapidly kills susceptible subpopulations in a concentration-
dependent manner at fCmax/MIC .6, whereas for prolonged sup-
pression of growth of resistant subpopulations an fAUC/MIC.25 is
required. An fCmax/MIC .6 can be attained with standard dosing
regimens for isolates with an MIC 0.125 mg/L, but very few of
these exist. Because of the low fCmax achieved in human plasma,
fAUC/MIC .25 is a more clinically feasible target. Target attain-
ment rates drop rapidly for isolates with reduced susceptibility to
colistin, necessitating TDM and the use of combination therapy.
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